References
- Food and Drug Administration. Oral Contraceptives and Thromboembolic Disorders, Current Drug Information. FDA, 1970; April 24
- Apelo R, Veloso I. Clinical experience with ethinyl-estradiol and D-norgestrel as an oral contraceptive. Fertil Steril 1975;26:283–8
- Nevinny Stickel J. German trial of an oral contra-ceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol. Acta Obstet Gynecol Scand Suppl 1987;144:19–21
- Gestodene Study Group 322. The safety and contra-ceptive efficacy of a 24-day low-dose oral contra-ceptive regimen containing gestodene 6014 and ethinyestradiol 15 pg. Eur J Contracept Reprod Health Care 1999;4\(Suppl 2):9–15
- Diisterberg B, Ellman H, Muller U, et al. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endo-crinol 1996;10:33–9
- Gast J, Grubb G. A review of cycle control with a low-dose oral contraceptive containing 7514 gestodene and 2014 ethinylestradiol. Gynecol Endo-crinol 1998;12 (Suppl 3):31–7
- EndrikatJ, Diisterberg B, Ruebig A, et al. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999;60:269–74
- Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 1992;8(Suppl 1):35–45
- Bannemerschult R, Hanker JP, Wiinsch C, et al. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 2014 ethinyl estradiol and 10014 levonorgestrel over six treatment cycles. Contraception 1997;56:285–90
- Hite RC, Bannemerschult R, Fox-Kuchenbecker, et al. Large observational trial of a new low-dose oral contraceptive containing 2014 ethinylestradiol and 10014 levonorgestrel (Miranova®) in Germany. Eur J Contracep Reprod Health Care 1999;4: 7–13
- Endrikat J, Muller U, Diisterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 2014 ethinylestradiol/ 7514 gestodene and 3014 ethinylestradiol/75 14 gestodene, with respect to efficacy, cycle control and tolerance. Contraception 1997;55: 127–31
- Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 10014 levonorgestrel in combination with 2014 ethinylestradiol. Contraception 1996;54: 299–304
- Fitzgerald C, Elstein M, Spona J. Effect of age on the response of the hypo thalamo-pituitary-ovarian axis to a combined oral contraceptive. Fertil Steril 1999; 71:1079–84
- Rosenbaum P, Schmidt P, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinyl-estradiol. Eur J Contracept Reprod Health Care 2000; 5:16–24
- Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contra-ception 1993;47:583–90
- Liidicke F, Sullivan H, Spona J, et al. Dose finding in a low-dose 21-day combined oral contraceptive containing gestoden. Contraception 2002;64:243–8
- Jung-Hoffman, Kuhl H. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception 1990;42: 423–38
- Kuhl H, Gahn G, Romberg G, et al. A randomized cross-over comparison of two low-dose oral contra-ceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception 1985;31:583–93
- Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996; 54:71–7
- Fitzgerald C, Feichtinger W, Spona J, et al. A comparison ofthe effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv. Contracept 1994;10:5–18
- Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (6014) and ethinyl estradiol (1514) on ovarian activity. Fertil Steril 1999;72:115